Abstract
Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.
Keywords: Coronary Intervention, IIIa inhibitors, GP IIb
Current Pharmaceutical Design
Title: GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention
Volume: 10 Issue: 4
Author(s): Dery J.P., Harrington R.A. and Tcheng J.E.
Affiliation:
Keywords: Coronary Intervention, IIIa inhibitors, GP IIb
Abstract: Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.
Export Options
About this article
Cite this article as:
Dery J.P. , Harrington R.A. and Tcheng J.E. , GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention, Current Pharmaceutical Design 2004; 10 (4) . https://dx.doi.org/10.2174/1381612043453306
DOI https://dx.doi.org/10.2174/1381612043453306 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Hypocholesterolemic Therapeutic Strategies: An Update
Recent Advances in DNA & Gene Sequences (Discontinued) Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Recent Developments in Female Hormonal Contraception
Current Women`s Health Reviews Using Simulations to Explore the Characteristics of CT Perfusion Calculations in the Assessment of Stroke
Current Medical Imaging Leptin in Thrombosis and Atherosclerosis
Current Pharmaceutical Design Standard Terminologies for Photoplethysmogram Signals
Current Cardiology Reviews Critical Roles of Insulin-Induced Senescence in Diabetic Vasculopathy
Vascular Disease Prevention (Discontinued) Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews The Lung in Immune-Mediated Disorder: Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Targeting Vascular Disease in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Aging and DNA Methylation
Current Chemical Biology Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry